Danaher Beheer
Beheer criteriumcontroles 3/4
De CEO Danaher is Rainer Blair, benoemd in Sep2020, heeft een ambtstermijn van 4.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 20.90M, bestaande uit 6.2% salaris en 93.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.014% van de aandelen van het bedrijf, ter waarde $ 22.63M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 14.5 jaar.
Belangrijke informatie
Rainer Blair
Algemeen directeur
US$20.9m
Totale compensatie
Percentage CEO-salaris | 6.2% |
Dienstverband CEO | 4.2yrs |
Eigendom CEO | 0.01% |
Management gemiddelde ambtstermijn | 5.8yrs |
Gemiddelde ambtstermijn bestuur | 14.5yrs |
Recente managementupdates
Recent updates
Understanding Danaher's Cautiousness
Oct 25Is There Now An Opportunity In Danaher Corporation (NYSE:DHR)?
Sep 28Danaher Q3 Preview: Market Share Gains In Molecular Testing
Sep 25Is Danaher Corporation (NYSE:DHR) Trading At A 32% Discount?
Sep 12Here's Why Danaher (NYSE:DHR) Can Manage Its Debt Responsibly
Aug 28Danaher: Lofty Price, Bright Future
Aug 22Danaher Corporation's (NYSE:DHR) Price In Tune With Earnings
Aug 13Danaher: Valuation Now Too High Even Compared To Own High Standards
Jul 16What Is Danaher Corporation's (NYSE:DHR) Share Price Doing?
Jun 23Mar Vista - Danaher: Headwinds Are Primarily Cyclical, Growth To Regain Momentum
Jun 20Is Danaher Corporation (NYSE:DHR) Worth US$263 Based On Its Intrinsic Value?
Jun 05Is Danaher (NYSE:DHR) A Risky Investment?
May 21It's Unlikely That Danaher Corporation's (NYSE:DHR) CEO Will See A Huge Pay Rise This Year
May 01Value Vs. Growth? Danaher Says Why Not Both?
Apr 25Danaher: All In On Life Sciences, And Market Update
Mar 27Is Now An Opportune Moment To Examine Danaher Corporation (NYSE:DHR)?
Mar 11Danaher Corporation's (NYSE:DHR) Price Is Out Of Tune With Earnings
Feb 10Bull Case Confirmed: Danaher Is Still One Of The Best Stocks To Buy Long-Term
Jan 30Is Danaher (NYSE:DHR) Using Too Much Debt?
Jan 12My Top 2024 Stock Pick: Danaher
Dec 27Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles
Nov 26RGA Investment Advisors - Danaher: Purity In The Crown Jewel Of Bioprocessing
Nov 19Why Danaher Is One Of My Favorite Long-Term Investments
Oct 26Danaher: Short-Term Headwinds, But Long-Term Tailwinds
Oct 17Should Danaher Investors Sell New Veralto Shares?
Oct 02Danaher Corporation's (NYSE:DHR) Intrinsic Value Is Potentially 18% Below Its Share Price
Sep 30Danaher: A Lost Year
Aug 30Third Point - Danaher: Don't Be Surprised If Growth Rate Moves To Low Teens
Aug 02Danaher: A Compounding Icon At A Fair Price
Jul 25These 4 Measures Indicate That Danaher (NYSE:DHR) Is Using Debt Reasonably Well
Jul 13Calculating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)
Jun 28Danaher: Seizing The Buying Opportunity In A Temporary Bioprocessing Slump
Jun 22At US$238, Is It Time To Put Danaher Corporation (NYSE:DHR) On Your Watch List?
Jun 15Danaher: A Great Chance To Buy This Long-Term Compounder
May 23With EPS Growth And More, Danaher (NYSE:DHR) Makes An Interesting Case
Apr 26Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Sep 27 2024 | n/a | n/a | US$4b |
Jun 28 2024 | n/a | n/a | US$4b |
Mar 29 2024 | n/a | n/a | US$4b |
Dec 31 2023 | US$21m | US$1m | US$4b |
Sep 29 2023 | n/a | n/a | US$4b |
Jun 30 2023 | n/a | n/a | US$5b |
Mar 31 2023 | n/a | n/a | US$6b |
Dec 31 2022 | US$20m | US$1m | US$6b |
Sep 30 2022 | n/a | n/a | US$7b |
Jul 01 2022 | n/a | n/a | US$6b |
Apr 01 2022 | n/a | n/a | US$6b |
Dec 31 2021 | US$17m | US$1m | US$5b |
Oct 01 2021 | n/a | n/a | US$6b |
Jul 02 2021 | n/a | n/a | US$5b |
Apr 02 2021 | n/a | n/a | US$5b |
Dec 31 2020 | US$10m | US$949k | US$4b |
Oct 02 2020 | n/a | n/a | US$3b |
Jul 03 2020 | n/a | n/a | US$3b |
Apr 03 2020 | n/a | n/a | US$3b |
Dec 31 2019 | US$7m | US$840k | US$2b |
Sep 27 2019 | n/a | n/a | US$2b |
Jun 28 2019 | n/a | n/a | US$2b |
Mar 29 2019 | n/a | n/a | US$2b |
Dec 31 2018 | US$5m | US$700k | US$2b |
Sep 28 2018 | n/a | n/a | US$3b |
Jun 29 2018 | n/a | n/a | US$3b |
Mar 30 2018 | n/a | n/a | US$3b |
Dec 31 2017 | US$4m | US$625k | US$2b |
Compensatie versus markt: De totale vergoeding ($USD 20.90M ) Rainer } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).
Compensatie versus inkomsten: De vergoeding van Rainer is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Rainer Blair (60 yo)
4.2yrs
Tenure
US$20,903,282
Compensatie
Mr. Rainer M. Blair serves as an Independent Non-Executive Director at Nestlé S.A. since April 20, 2023. He serves as President, Chief Executive Officer and Director at Danaher Corporation since September...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder & Chairman | 41.8yrs | geen gegevens | 6.02% $ 10.1b | |
President | 4.2yrs | US$20.90m | 0.014% $ 22.8m | |
Co-Founder & Director | 41.8yrs | geen gegevens | 4.86% $ 8.2b | |
CFO & Executive VP | 5.8yrs | US$7.50m | 0.0053% $ 8.9m | |
Senior VP & Chief Science Officer | 3.9yrs | US$7.20m | 0.00037% $ 622.9k | |
Senior Vice President of Human Resources | 2.6yrs | US$5.25m | 0.00015% $ 252.5k | |
VP & Chief Accounting Officer | 2.8yrs | geen gegevens | 0.00081% $ 1.4m | |
Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
Senior VP | 8.8yrs | US$3.56m | 0.0028% $ 4.7m | |
Senior Vice President of Corporate Development | 14.8yrs | geen gegevens | 0.0033% $ 5.5m | |
Senior Vice President of Strategic Development | 10.5yrs | geen gegevens | 0.0067% $ 11.2m | |
Executive VP of Biotechnology Group & CEO of Cytiva | less than a year | geen gegevens | 0.0020% $ 3.4m |
5.8yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van DHR is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder & Chairman | 41.8yrs | geen gegevens | 6.02% $ 10.1b | |
President | 4.2yrs | US$20.90m | 0.014% $ 22.8m | |
Co-Founder & Director | 41.8yrs | geen gegevens | 4.86% $ 8.2b | |
Independent Director | 25.8yrs | US$338.13k | 0.011% $ 19.0m | |
Independent Director | 21.3yrs | US$351.13k | 0.0054% $ 9.1m | |
Independent Director | 15.8yrs | US$338.13k | 0.0024% $ 4.0m | |
Independent Director | 7.8yrs | US$318.13k | 0% $ 0 | |
Member of Scientific Advisory Board | 3.6yrs | geen gegevens | geen gegevens | |
Lead Independent Director | 18.9yrs | US$382.13k | 0.0057% $ 9.6m | |
Independent Director | 13.2yrs | US$318.13k | 0% $ 0 | |
Independent Director | 5yrs | US$318.13k | 0% $ 0 | |
Director | 5yrs | US$318.13k | 0% $ 0 |
14.5yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van DHR zijn ervaren en ervaren (gemiddelde ambtstermijn van 14.5 jaar).